Pfizer(US:PFE) Benzinga·2025-12-05 17:01Core Insights - Financial giants are showing a bearish sentiment towards Pfizer, with 65% of traders exhibiting bearish tendencies compared to 35% who are bullish [1] - The options trading analysis indicates a price target range for Pfizer between $20.0 and $35.0 over the past quarter [2] - Recent unusual options activity highlights significant trades, including both puts and calls, reflecting mixed market sentiment [7][10] Options Trading Analysis - A total of 20 unusual trades were identified for Pfizer, with 2 puts valued at $543,015 and 18 calls valued at $775,183 [1] - The volume and open interest data for Pfizer's options provide insights into liquidity and trader interest, particularly within the $20.0 to $35.0 strike price range [3] - Recent trading patterns show a mix of bullish and bearish trades, with notable call and put volumes indicating varying market expectations [7] Company Overview - Pfizer is a leading pharmaceutical company with annual sales around $60 billion, primarily from prescription drugs and vaccines [8] - Key products include the pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis, with international sales accounting for 40% of total revenue [8] - Recent analyst opinions suggest a mixed outlook, with one analyst lowering the rating to Neutral with a price target of $26, while another maintains a Buy rating with a target of $35 [10] Current Market Position - Pfizer's stock is currently trading at $25.91, reflecting a 0.82% increase, with a trading volume of over 13 million shares [12] - The anticipated earnings release is expected in 60 days, which may influence future trading activity and market sentiment [12]